about
Prototype development and preclinical immunogenicity analysis of a novel minimally invasive electroporation device.Electroporation advances in large animals.Efficient gene delivery and silencing of mouse and human pancreatic isletsA multi-head intradermal electroporation device allows for tailored and increased dose DNA vaccine delivery to the skinProlonged survival and improved glycemia in BioBreeding diabetic rats after early sustained exposure to glucagon-like peptide 1Transfection of rat pancreatic islet tissue by polymeric gene vectors.Encapsulation of plasmid DNA in calcium phosphate nanoparticles: stem cell uptake and gene transfer efficiencyAntigen-specific therapeutic approaches in Type 1 diabetesElucidating the Kinetics of Expression and Immune Cell Infiltration Resulting from Plasmid Gene Delivery Enhanced by Surface Dermal Electroporation.Diabetes mellitus: new challenges and innovative therapies.Treatment with MOG-DNA vaccines induces CD4+CD25+FoxP3+ regulatory T cells and up-regulates genes with neuroprotective functions in experimental autoimmune encephalomyelitis.Contactless magneto-permeabilization for intracellular plasmid DNA delivery in-vivo.Gene gun-mediated DNA vaccination enhances antigen-specific immunotherapy at a late preclinical stage of type 1 diabetes in nonobese diabetic mice.In vivo delivery of a microRNA-regulated transgene induces antigen-specific regulatory T cells and promotes immunologic tolerance.Skin Transfection Patterns and Expression Kinetics of Electroporation-Enhanced Plasmid Delivery Using the CELLECTRA-3P, a Portable Next-Generation Dermal Electroporation DeviceDNA vaccines for autoimmune diseases.Treatment of diabetes with glucagon-like peptide-1 gene therapy.Electroporation-enhanced delivery of nucleic acid vaccines.Enhanced Delivery of DNA or RNA Vaccines by Electroporation.Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques.Engineered Epidermal Progenitor Cells Can Correct Diet-Induced Obesity and Diabetes.Immunity against a therapeutic xenoprotein/Fc construct delivered by gene transfer is reduced through binding to the inhibitory receptor FcγRIIb.A multi-head intradermal electroporation device allows for tailored and increased dose DNA vaccine delivery to the skin.Tolerogenic β2-glycoprotein I DNA vaccine and FK506 as an adjuvant attenuates experimental obstetric antiphospholipid syndrome.
P2860
Q30395101-E485C3A7-1FD1-4785-BD19-67A1B8E7E2ACQ30476834-89F1E9AB-3AD3-4968-8E27-0B3B0349B655Q33547705-18B6B408-24A3-486E-ACE3-481815210685Q33723334-77DBAE60-3879-4652-BE2F-7AEEDC3AD106Q33901714-96033609-E6DD-4BE0-A23F-39F2ACE74200Q33985556-BEC3A406-00F7-4333-ACEE-88DFE8F0906DQ34121750-09366EB6-E42B-4A66-8498-72356558BC44Q35762883-BC3E7651-ED67-48A3-BE56-B4D75D2DA279Q35826661-C1A417F1-3BAF-4D7A-BB89-F2F2DED68805Q36117595-E99DD3D5-0DA7-4B75-A8C1-4A9F5EFAA830Q36299378-97BD3A60-5011-4779-9383-9962F2BB2606Q36694873-22CD03A6-4794-4EA8-9FDD-46039F45530DQ36993836-42A39EC1-0FD0-4ACB-87F8-0999580F8CA4Q37472002-FA55C8D1-44E8-4B22-A190-8CEAD7FEEED2Q37550619-31ADEF2B-5EF8-4212-8037-B97A65F0A0A7Q37590340-8E4CC89A-2323-4963-99F4-8FE02A7691E8Q37804398-799405CE-AF51-4135-ACED-C8E24A16501DQ38285418-6C2CA788-81B2-496B-BAEF-EED7EED8CBECQ40420214-3B7032C4-D25C-4B76-AFED-497EEEFE42B6Q42410705-F391EDA0-49F0-492F-9EE7-1579CF169620Q45870446-B4A0787C-7730-4EAC-BDE3-1CEC89DE080CQ45872071-FD4A2FCF-B210-41B0-99B3-A46B8BE12D08Q53272516-504552B1-EA6E-4AB1-9DD4-E4F947BC0D7CQ55260402-D5862F4D-73BA-4D53-9297-73854AFC1930
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Plasmid-based gene therapy of diabetes mellitus.
@ast
Plasmid-based gene therapy of diabetes mellitus.
@en
type
label
Plasmid-based gene therapy of diabetes mellitus.
@ast
Plasmid-based gene therapy of diabetes mellitus.
@en
prefLabel
Plasmid-based gene therapy of diabetes mellitus.
@ast
Plasmid-based gene therapy of diabetes mellitus.
@en
P2093
P2860
P356
P1433
P1476
Plasmid-based gene therapy of diabetes mellitus.
@en
P2093
Draghia-Akli R
Prud'homme GJ
P2860
P2888
P304
P356
10.1038/SJ.GT.3302907
P577
2007-01-11T00:00:00Z